• book

From the Publisher

This industry standard encyclopedia on pharmaceutical manufacturing processes has been completely updated to include FDA drugs approved up to the summer of 2004. The encyclopedia gives details for the manufacture of 2226 pharmaceuticals that are being marketed as a trade-named product somewhere in the world. Each entry includes:

ò Therapeutic function
ò Chemical and common name
ò Structural Formula
ò Chemical Abstracts Registry no.
ò Trade name, manufacturer, country, and year introduced
ò Raw Materials
ò Manufacturing Process

In addition, references are also cited under each drug's entry to major pharmaceutical works where additional information can be obtained on synthesis and the pharmacology of the individual products.
Published: Elsevier Science an imprint of Elsevier Books Reference on
ISBN: 9780815518563
List price: $1,010.00
Read on Scribd mobile: iPhone, iPad and Android.
Availability for Pharmaceutical Manufacturing Encyclopedia, 3rd Edition
With a 30 day free trial you can read online for free
  1. This book can be read on up to 6 mobile devices.

Related Articles

4 min read

4 Ways to Shoot Down Skyrocketing Drug Prices

WHEN POLITICIANS DECRIED the drug company Mylan’s decision to increase the price of an EpiPen by 500% in less than six years, their indignation rang familiar. After all, Congress had just wrapped up a series of hearings examining Valeant Pharmaceuticals’ decision to raise the price of a single vial of its heart medication Isuprel from $180 to $1,472. A few months earlier, Turing Pharmaceuticals CEO Martin Shkreli had been deemed the “most hated man in America” after increasing the price of the antiparasitic drug Daraprim by 5,000% in one month, from $13.50 per pill to $750. Shkreli showed litt
Bloomberg Businessweek
5 min read

How Much Is a Miracle Worth?

Caroline Chen • New one-shot medicines could eliminate years of costly care • “So $1 million upfront…that’s not much, if they’re healed for life” Sofia Priebe, 14, is slowly going blind. Her parents were devastated when they were told there’s no treatment for the genetic mutation that’s causing her retinas to deteriorate. For the dozen years since Sofia received that diagnosis, her mother has lived every parent’s nightmare—being powerless to help her suffering child. Now a gene therapy for a similar form of blindness is expected to receive U.S. Food and Drug Administration approval this ye
Bloomberg Businessweek
5 min read

Pharma’s Worst Nightmare

Doni Bloomfield, with Hui Li Pharmaceutical executives initially celebrated Donald Trump’s election, expecting the businessman to be friendlier to their industry than Hillary Clinton, a tough critic. But worries about his ire soon set in, and the fears proved justified on Jan. 11, when Trump said the industry was “getting away with murder.” His prescription for reducing drug prices: make pharmaceutical companies bid for the government’s business. The mere threat of Washington using its potentially huge bargaining clout to hold down prices has given the industry a massive headache. Unlike oth